Monday, August 22, 2022 9:29:25 AM
The aduhelm disaster works in our favor. It shows how desperate the FDA is for something/anything that shows a glimmer of hope.
Add on the amyloid fiasco, and we have an agency that is wants a narrative change. Perfect pivot opportunity.
Embrace change, hope, new MOA, precision medicine, safety, economic benefit etc. lots of good buzz words to make them look good. A shame that politics and perception works that way but this time it’s in our favor.
If a good amount of patients improve, stabilize, etc. How bad would they look to say we need more data? I guess loads of crappy intravenous exploding head data is better than a smaller amount of positive safe data? Not sure it makes sense but then again so many things that happen in government don’t.
Desperate times calls for change.
FDA, Biden, CNS sufferers need hope and change and more importantly a win. It’s innovation. It looks good. It’s safe. Seems like precedent got thrown out with aduhelm, vaccine, etc.
Oh wait only some people improved and stabilized and it’s completely safe. Hold on we need to wait. Keep them on that other crap that barely works at all. Funny world we live in.
Let’s see what happens
Add on the amyloid fiasco, and we have an agency that is wants a narrative change. Perfect pivot opportunity.
Embrace change, hope, new MOA, precision medicine, safety, economic benefit etc. lots of good buzz words to make them look good. A shame that politics and perception works that way but this time it’s in our favor.
If a good amount of patients improve, stabilize, etc. How bad would they look to say we need more data? I guess loads of crappy intravenous exploding head data is better than a smaller amount of positive safe data? Not sure it makes sense but then again so many things that happen in government don’t.
Desperate times calls for change.
FDA, Biden, CNS sufferers need hope and change and more importantly a win. It’s innovation. It looks good. It’s safe. Seems like precedent got thrown out with aduhelm, vaccine, etc.
Oh wait only some people improved and stabilized and it’s completely safe. Hold on we need to wait. Keep them on that other crap that barely works at all. Funny world we live in.
Let’s see what happens
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
